Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough

Nattapon Riengvirodkij; Mookmanee Taechikantaphat; Pichayut Ampapol; Theethach Kovorakul; Sapon Intaranat; Nick Costa; Walasinee Sakcamduang

doi:10.1371/journal.pone.0333526

Back

Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough

Journal article

Open access

Peer reviewed

Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough

Nattapon Riengvirodkij, Mookmanee Taechikantaphat, Pichayut Ampapol, Theethach Kovorakul, Sapon Intaranat, Nick Costa and Walasinee Sakcamduang

PloS one, Vol.20(9), e0333526

2025

DOI: https://doi.org/10.1371/journal.pone.0333526

PMID: 41021602

Files and links (1)

pdf

Published899.52 kBDownload View

CC BY V4.0, Open Access

Abstract

Animals

Cough - drug therapy

Cough - veterinary

Dog Diseases - drug therapy

Dog Diseases - physiopathology

Dogs

Drug Therapy, Combination

Exercise Tolerance - drug effects

Female

Hypertension, Pulmonary - drug therapy

Hypertension, Pulmonary - physiopathology

Hypertension, Pulmonary - veterinary

Male

Prospective Studies

Sildenafil Citrate - therapeutic use

Pulmonary hypertension (PH) in dogs, characterized by abnormally high blood pressure in the pulmonary arteries, presents a management challenge, and adjunctive therapies for the standard treatment of sildenafil are needed. This study aimed to determine whether the nutraceutical Perna canaliculus oil (PCSO-524), a marine lipid extract with anti-inflammatory properties, provides additional clinical benefits to dogs with PH. In a prospective, randomized, placebo-controlled trial, seventeen client-owned dogs diagnosed with PH were assigned to receive either PCSO-524 or a placebo as an add-on to their sildenafil-based therapy for 70 days. Key outcomes were evaluated using owner-assessed clinical scores for exercise tolerance and coughing, alongside echocardiographic measurements. The PCSO-524 group demonstrated a statistically significant improvement in exercise tolerance scores by day 70 (P = 0.009). This group also showed a greater reduction in coughing scores compared to the placebo group between day 35 and day 70 (P = 0.03). While the tricuspid regurgitation pressure gradient (TRPG), an estimate of pulmonary pressure, decreased significantly over time in all dogs (P = 0.001), no significant difference was found between the groups for this specific measure. These results indicate that PCSO-524 can serve as a beneficial adjunctive therapy for improving important clinical signs, such as exercise tolerance and coughing, in dogs with PH. This suggests it may be a valuable addition to standard management for enhancing quality of life.

Details

Title: Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
Authors/Creators: Nattapon Riengvirodkij - Mahidol University
Mookmanee Taechikantaphat - Mahidol University
Pichayut Ampapol - Mahidol University
Theethach Kovorakul - Mahidol University
Sapon Intaranat - Mahidol University
Nick Costa - College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Australia
Walasinee Sakcamduang - Mahidol University
Publication Details: PloS one, Vol.20(9), e0333526
Publisher: Public Library of Science
Identifiers: 991005816849407891
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

3 File views/ downloads

4 Record Views